- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03346954
Impact of [11C]-Methionine PET/MRI in the Detection of Pituitary Adenomas Secreting ACTH and Causing Cushing's Disease (IMPEC)
Cushing's disease is characterized by the existence of a benign pituitary tumor developed from corticotropic cells responsible for excessive ACTH secretion. This results in hypercorticism causing high morbidity and mortality and severely impairing quality of life. The etiological diagnosis is based on Magnetic Resonance Imaging (MRI). However, pituitary MRI revealed a pituitary tumor in only 60% of patients. The diagnostic procedure is complicated by the existence of extra pituitary tumors responsible for ACTH ectopic secretion. This rare etiology imposes, in the absence of typical pituitary image, the realization of catheterization of the lower petrosal sinuses. Treatment of Cushing's disease is based on transsphenoidal surgical management, even in the absence of a formal MRI image, if pituitary origin is confirmed by the catheterization. Although pituitary surgery without identified target is part of French recommendations, this surgery is associated with a high risk of failure and morbidity. Optimization of the management of patients' with Cushing's disease thus requires the improvement of the diagnostic methods.
Hypothesis of our study is that [11C] MET MRI-PET may be performed as a first-line MRI for suspected Cushing's disease and may limit indications for catheterization of lower petrosal sinuses. Its localizing value should also make it possible to improve the surgical results with a better identification of the adenoma
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bron, France, 69677
- Service de Médecine Nucléaire - Hospices Civils de Lyon
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged 18 years old or over
- Patient with a diagnosed Cushing's disease according to the French "protocole national de diagnostic et de soins (PNDS)"
- Patient who underwent a MRI pituitary for diagnostic purposes
- Patient who have undergone catheterization of the lower petrosal sinuses (if MRI does not detect pituitary adenoma) and have a result in favor of a central secretion of ACTH
- Patient having an indication of surgical excision of the adenoma
- Patient with a micro-adenoma (less than 1 cm in diameter) if the tumor is visualized on MRI
- Patient for which informed and written consent to participate has been obtained.
Exclusion Criteria:
- - Patient participating in another study
- Patient with a pituitary macro-adenoma with visual impairment
- Patient with ACTH-dependent Cushing's syndrome secondary to ectopic ACTH secretion
- Patient with recurrence and / or history of pituitary adenoma excision
- Patient with a contraindication to pituitary surgery or general anesthesia
- Pregnant woman, breastfeeding or old enough to have children but without effective recognized contraception
- Contra-indication to the realization of an MRI: permanently fixed metal parts (pacemaker, cerebral clip, cephalic end piercing, cochlear implant, pin or screw for recent bone fracture, dental equipment, metal splinters), claustrophobia
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patients with Cushing's disease
Implementation of [11C]-Methionine PET/MRI
|
Implementation [11C]-Methionine PET/MRI performed for each patient in one place (department of nuclear medicine of the Hospices Civils de Lyon).
The [11C]-Methionine PET/MRI will be performed after a pituitary MRI and before a transsphenoidal surgery.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensitivity of [11C]-Methionine PET/MRI
Time Frame: Within 3 months and 3 weeks after inclusion
|
Sensitivity of [11C]-Methionine PET/MRI to correctly localizes the pituitary corticotropic adenoma in comparison with the sensitivity of the pituitary MRI.
The gold standard being the localization defined by anatomopathological analysis on operative resection.
|
Within 3 months and 3 weeks after inclusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
False negatives and false positives description
Time Frame: Within 3 months and 3 weeks after inclusion
|
Description of false negatives and false positives [11C]-Methionine PET/MRI to identify and localize the microadenoma.
Characteristics of unidentified adenomas will be described using: volume, localization, type of fixation
|
Within 3 months and 3 weeks after inclusion
|
Description of identified microadenomas
Time Frame: Within 3 months and 3 weeks months after inclusion
|
Proportion of microadenomas identified by the [11C]-Methionine PET/MRI as a function of the degree of aggressiveness of the adenoma, evaluated by the number of mitoses, the level of expression of Ki67 and p53.
|
Within 3 months and 3 weeks months after inclusion
|
Comparison of [11C]-Methionine PET/MRI and pituitary MRI
Time Frame: Within 3 months and 3 weeks months after inclusion
|
Study of the concordance between the results of [11C]-Methionine PET/MRI and pituitary MRI
|
Within 3 months and 3 weeks months after inclusion
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: BOURNAUD Claire, MD, Hospices Civils de Lyon
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Endocrine System Diseases
- Endocrine Gland Neoplasms
- Hypothalamic Diseases
- Hypothalamic Neoplasms
- Supratentorial Neoplasms
- Brain Neoplasms
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Hyperpituitarism
- Pituitary Diseases
- Adenoma
- Pituitary Neoplasms
- ACTH-Secreting Pituitary Adenoma
- Pituitary ACTH Hypersecretion
Other Study ID Numbers
- 69HCL17_0167
- 2017-002721-38 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cushing's Disease
-
Sheffield Teaching Hospitals NHS Foundation TrustHRA PharmaCompleted
-
RECORDATI GROUPRecruitingEndogenous Cushing's SyndromeUnited States, Germany, France
-
Corcept TherapeuticsCompleted
-
Cortendo ABCompletedEndogenous Cushing's SyndromeUnited States, Bulgaria, Denmark, France, Greece, Hungary, Israel, Italy, Netherlands, Poland, Romania, Spain
-
Wuerzburg University HospitalCompletedEndogenous Cushing's SyndromeGermany
-
Cortendo ABCompletedEndogenous Cushing's SyndromeUnited States, Serbia, Denmark, Italy, Spain, Poland, Belgium, Bulgaria, Canada, Czechia, France, Germany, Israel, Netherlands, Turkey
-
University of OxfordAstraZenecaCompletedIatrogenic Cushing's DiseaseUnited Kingdom
-
Andrea M. IsidoriCompletedCushing's Syndrome CardiomyopathyItaly
-
Sparrow PharmaceuticalsActive, not recruitingCortisol; Hypersecretion | Cortisol Overproduction | Cushing's Syndrome I | Cushing Disease Due to Increased ACTH Secretion | Cortisol Excess | Ectopic ACTH SecretionUnited States, Bulgaria, Romania
-
Memorial Sloan Kettering Cancer CenterRecruitingCushing Syndrome | Cushing's Disease | Cushing DiseaseUnited States
Clinical Trials on [11C]-Methionine PET/MRI
-
Hospices Civils de LyonRecruiting
-
Massachusetts General HospitalRecruitingDiabetes | Aortic Valve Stenosis | Heart Failure With Normal Ejection Fraction | Left Ventricular HypertrophyUnited States
-
Hospices Civils de LyonCompletedPosterior Brain Fossa Tumors in ChildrenFrance
-
Masaryk Memorial Cancer InstituteActive, not recruiting11C-methionine in Diagnostics and Management of Glioblastoma Multiforme Patients (GlioMET) (GlioMET)Glioblastoma MultiformeCzechia
-
University of PennsylvaniaRecruiting
-
University of British ColumbiaBritish Columbia Cancer AgencyUnknownPrimary HyperparathyroidismCanada
-
Turku University HospitalCompleted
-
University of PennsylvaniaRecruitingTauopathiesUnited States
-
St. Jude Children's Research HospitalRecruitingHodgkin Lymphoma | Osteosarcoma | Ewing Sarcoma | Ependymoma | Medulloblastoma | Non Hodgkin Lymphoma | Neuroblastoma | Craniopharyngioma | Rhabdomyosarcoma | Other | Brain Stem Glioma | Brain Tumors and/or Solid Tumors Including | High Grade CNS Tumors | Low Grade CNS TumorsUnited States
-
St. Jude Children's Research HospitalAvailableHead and Neck Neoplasms | Central Nervous System TumorUnited States